NPPB and cancer: Our previous clinical study based on 40 patients showed that the PDE3 inhibitor was safe even among patients with heart diseases who presented elevated preoperative BNP levels (≥30 pg/mL)28 while few clinical studies have provided information on the safety of the other PDE inhibitors administration for patients with cancer.